CSRH news Consorteum Holdings, Inc. Executes Exclusive

New Post Public Reply Private Reply Replies (0) Message Board
i_like_bb_stock
150
CSRH news Consorteum Holdings, Inc. Executes Exclusive Distribution Contract with DevLex Ltd. GlobeNewswire "Press Releases"
ATLANTA , March 27, 2018 (GLOBE NEWSWIRE) -- via NetworkWire Consorteum Holdings, Inc. ("Consorteum" or the "Company" (OTCPK:CSRH), a software development company and mobile device solutions provider, today announced that its wholly owned subsidiary, 359 Mobile Inc. (359), has finalized terms and executed an exclusive distribution agreement with DevLex Ltd. The distribution agreement creates an exclusive alliance for the distribution of the DevLex Predictive Analytics Platform (DV-PA) with 359s Universal Mobile Interface (UMI). The DV-PA will allow real time mobile analytic solutions to be developed for markets such as FinTech, Sports Wagering, Commodities management and other verticals that utilize significant historical data sets. The first utilization of the DV-PA will be a sports based analytic mobile offering projected for release in the second quarter of 2018.

Consorteum CEO Craig Fielding stated, We are extremely pleased that we have finalized a distribution contract with DevLex and anticipate the first product release utilizing the DV-PA platform in the second quarter of 2018. This first offering will give everyone a clear understanding of the tremendous capabilities and potential scale of the mobile solutions Consorteum intends to provide moving forward.
Ian Copeman (Founder\MD of DevLex) commented, The execution of our exclusive distribution contract with Consorteum and 359 Mobile is a cornerstone that both companies will continue to build upon. The opportunities that we foresee for the DV-PA offering are expansive and we are looking forward to our first joint release shortly.
About Consorteum Holdings, Inc.
Consorteum Holdings, Inc. is a mobile platform company focused on delivering compliant complex mobile-based transactions through a mix of partnerships, license agreements, and joint venture revenue share arrangements. The Company is focused on FinTech, otherwise known as next-generation financial technology. Consorteum aims to capitalize on the broad variety of technological interventions into personal and commercial transactions by focusing its efforts and resources where it can leverage its expertise in direct and vertical based solutions. For more information about the Company, please visit: http://www.Consorteum.com
About DevLex Ltd.
Founded to develop complex mobile application solutions over 10 years ago, DevLex continues to develop leading edge solutions for the mobile market. The most recent innovation has been the significant investment in its DevLex DV-PA framework, which allows real time analytics and predictive analytics to be developed and deployed to mobile devices. The solution will be targeted at any type of FinTech solution utilizing complex historic data sets. For more information about DevLex, please visit:http://www.devlex.com
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties any of which could cause actual results to differ materially from those expressed in or implied by the forward looking statements. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, its limited financial resources, domestic and global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws impacting the Company and its business.
We assume no obligation to revise or update any forward-looking statement except as otherwise required by law.
Contact:
Patrick Shuster Chief Operating Officer patrick@consorteum.com (888) 603-5161
SOURCE: Consorteum Holdings, Inc.
NNW Contact:
NetworkNewsWire(NNW) New York, New York www.NetworkNewsWire.com 212.418.1217 Office Editor@NetworkNewsWire.com




Source: Consorteum Holdings, Inc.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 15

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

Eco Wave Power Expands Wave Energy Project in Europe

Updated Category News Views 229

Eco Wave Power Initiates Key Infrastructure Enhancements Eco Wave Power Global AB (publ) (NASDAQ: WAVE) is excited to unveil plans for crucial upgrades at its groundbreaking wave energy project. This groundbreaking initiative is set to harness ocean wave energy to produce clean electricity efficiently. Eco Wave Power, recognized as a leading company in onshore wave energy...

Continue Reading
Key Managerial Transactions Reported by Danske Bank A/S

Updated Category News Views 162

Recent Mandatory Transaction Notifications by Danske Bank A/S Danske Bank A/S is committed to transparency in financial transactions involving its managerial personnel. This communication signifies the bank's adherence to the EU Market Abuse Regulation and the requirements set by the Danish Financial Supervisory Authority (FSA) and Nasdaq Copenhagen. Understanding...

Continue Reading
Strategic Insights into Symbotic's Options Market Activity

Updated Category News Views 187

Overview of Options Activity for Symbotic Recently, significant investors have demonstrated a notably bearish outlook on Symbotic. This trend has been evidenced by the options activity surrounding the company's stock, symbolized by SYM. The strong presence of whales entering the market indicates a shift in investor sentiment, with nuances that are crucial for...

Continue Reading
South Coast AQMD Takes Action on Oil Facilities During Violations

Updated Category News Views 267

South Coast AQMD Addresses Oil Site Violations In a determined effort to safeguard public health and air quality, the South Coast Air Quality Management District (South Coast AQMD) has recently taken enforcement action against three oil and gas facilities in Los Angeles. These actions were prompted by public complaints and confirmed violations of air quality regulations,...

Continue Reading
BAM UK & Ireland and LoadSpring Solutions Innovate Project Management

Updated Category News Views 199

BAM UK & Ireland and LoadSpring Solutions Innovate Project Management BAM UK & Ireland, a prominent name in the construction and engineering sector, has taken a bold step forward by partnering with LoadSpring Solutions. This collaboration aims to revolutionize project management through an innovative solution known as LoadSpring INSIGHTS™. This groundbreaking platform...

Continue Reading